Adamis Pharmaceuticals announced that it has submitted an Investigational New Drug application to the FDA for APC-100 for the treatment of prostate cancer. Following approval, Adamis plans to begin Phase 1/2a clinical studies with APC-100 in men with castrate-resistant prostate cancer. Each patient will be assessed for toxicity, biochemical responses (prostate specific antigen), radiographic and clinical responses.
APC-100 is an orally available antiandrogenic/anti-inflammatory, signal transduction inhibitor drug.
For more information visit www.adamispharmaceuticals.com.